Digestion

Original Paper

MIP-3α Expression in Macrophages Is NOD Dependent

M. Hausmann[a]   C. Zeitler[c]   A. Weber[b]   M. Krebs[a]   S. Kellermeier[a]
P. Rosenstiel[e]   C. de Vallière[a]   K. Kosovac[c]   M. Fried[a]   E. Holler[d]   G. Rogler[a]

[a]Division of Gastroenterology and Hepatology and [b]Institute of Pathology, University Hospital of Zurich, Zurich, Switzerland; [c]Department of Internal Medicine I, University of Regensburg, [d]Department of Haematology/Oncology, University Medical Centre, Regensburg, and [e]Institute of Clinical Molecular Biology, Christian-Albrechts-University, Kiel, Germany

Abstract

Background: The first identified susceptibility gene for Crohn's disease, *NOD2*, acts as a sensor for the bacterial-wall peptidoglycan fragment muramyl dipeptide (MDP) and activates the transcription factor nuclear factor-κB (NF-κB). Upon NF-κB activation, intestinal macrophages (IMACs) induce expression of macrophage inflammatory protein (MIP)-3α to attract memory T lymphocytes. We therefore investigated the influence of NOD2 ligation of IMAC differentiation and functional MIP-3α induction. *Methods:* Human embryonal kidney HEK293 cells were transfected with NOD2 wild-type (NOD2WT) and the NOD2 SNP13 variant (NOD2L1007fsinsC) and stimulated with MDP. Recruitment of CD45R0+ and Th17 cells was determined by immunohistochemistry. *Results:* Endogenous NOD2 stimulation was followed by a dose-dependent increase in MIP-3α secretion in MONO-MAC-6 (MM6) cells. MIP-3α mRNA was also significantly (* p < 0.05) induced in HEK293 transfected with NOD2WT via MDP ligation. In vivo cell-cell contacts between IMACs and CD45R0+ memory T cells as well as recruitment of Th17 cells in patients of NOD2 variants were unchanged as compared to wild-type patients. *Conclusion:* Our data demonstrate a dose-dependent increase in MIP-3α secretion in the human myeloid cell line MM6 upon MDP. However, MIP-3α-driven recruitment of Th17 cells or CD45R0+ memory T lymphocytes is not affected in patients carrying heterozygous NOD2 variants.

Copyright © 2012 S. Karger AG, Basel

Introduction

Antigens passing over the tightly regulated intestinal epithelial barrier are recognized and cleared by intestinal macrophages (IMACs). In healthy individuals monocytes differentiate into tolerant IMACs with a prototypic phenotype lacking activation markers such as toll-like receptors (TLRs) 2 and 4 [1]. This is important in maintaining effective tolerance to the natural microbial flora thus preventing chronic inflammation in response to commensal bacteria. Consequently no or only low activation of pro-inflammatory transcription factors such as nuclear factor-κB (NF-κB) is found in normal mucosa [2]. But normal IMACs may still express intracytoplasmatic pattern recognition receptors (PRRs) such as TLR9 or NOD2. This enables IMACs to react to invading bacteria. NOD2

Martin Hausmann, PhD
Clinic of Gastroenterology and Hepatology
Department of Internal Medicine, University Hospital of Zürich
CH–8091 Zürich (Switzerland)
Tel. +41 442 559 916, E-Mail martin.hausmann@usz.ch

detects the bacterial-wall component muramyl dipeptide (MDP). MDP sensing via the leucine-rich repeat domain of NOD2 induces activation of NF-κB in monocytes/macrophages as well as in intestinal epithelial cells [3–6]. By activation of the NF-κB signaling pathway numerous proinflammatory genes are induced, these include interleukin (IL)-1β, IL-6, IL-8, TNF, GM-CSF or chemokines and their receptors, such as macrophage inflammatory protein (MIP)-3α [7–9].

Variants of NOD2 were the first genetic susceptibility factors identified for Crohn's disease (CD), an inflammatory bowel disease (IBD). The three most frequent single-nucleotide polymorphisms (SNP) are SNP 8, 12 and 13 [10, 11]. These SNPs are associated with ineffective MDP binding and a subsequent inability to activate defense mechanisms which results in reduced secretion of antimicrobial peptides and chemokines and increased bacterial translocation in animal models [5, 12, 13]. Using FISH technology, we detected mucus-associated bacteria in CD patients' mucosa but not in control specimens [14]. Accumulation of endotoxin in the intestinal tissue of CD patients reflected the NOD2 genotype: patients with heterozygous SNP8 or SNP13 variants revealed notably stronger endotoxin staining than patients with SNP12 or the wild-type (WT) variant indicating more transepithelial bacterial translocation or ineffective clearance of bacterial products [14]. Increased activation of NF-κB was found in the mucosa of CD patients, and this was even greater in patients with NOD2 variants [14].

MIP-3α – also called liver and activation-induced chemokine (LARC) [15], Exodus [16] or SCYA20 – is a CC chemokine which has been reported to attract memory T cells and immature dendritic cells (DCs) [17–23]. In contrast to many other chemokines MIP-3α has a specific receptor: it binds almost exclusively to the chemokine receptor CCR6, which is expressed on immature DCs and memory T cells, but also on B lymphocytes [22, 24–28]. Annunziato et al. [29] observed the presence of CCR6+ IL-17-producing T cells in the gut. Epithelial cells are thought to be an important source of MIP-3α production [16]. Other cell types, such as endothelial cells, fibroblasts, and monocytes are also known to express MIP-3α [28, 30]. High MIP-3α mRNA and protein expression are induced during the specific differentiation of IMACs as shown in previous studies from our laboratory [31]. Similarly, MIP-3α mRNA was found to be highly expressed in differentiated macrophages in the lung [28]. Izadpanah et al. [32] demonstrated constitutive MIP-3α mRNA expression in intestinal epithelium

and an upregulation by pro-inflammatory cytokines or in response to infection with bacterial pathogens. Kwon et al. [33] found significantly elevated MIP-3α mRNA and protein levels in CD patients compared with controls or ulcerative colitis (UC) patients. CCR6 expression in T cells and chemotactic response to MIP-3α is thought to be restricted to the CD45R0+ memory T cell population [27]. These data suggest that CCR6 functions on memory T cells that home to mucosal sites as part of an immune response [26]. Professional antigen-presenting and MIP-3α-secreting IMACs may serve as a contact point for CD45R0+ memory T and B cells and subpopulations of DCs [31].

As translocated bacterial components can activate NF-κB in a NOD2 genotype-specific manner, we hypothesized that a lack of detection of invading bacteria or bacterial material could be followed by impaired recruitment of MIP-3α-dependent lymphocytes in individuals with NOD2 variants. The aim of the study was therefore to establish a link between NOD2-mediated MIP-3α expression and lymphocyte recruitment in CD patients.

Materials and Methods

Patients
Primary human cells were obtained from surgical specimens taken from healthy areas of the mucosa of patients undergoing surgery for colorectal carcinoma or from the mucosa of patients with CD. Histology was performed on surgical specimens by a pathologist. The medical treatment of the patients is listed in online supplementary table 1 (for all online suppl. material, see www.karger.com/doi/10.1159/000335423). Of a total of 43 subjects, 18 were male and 25 were female. The patients were between 16 and 74 (mean 43.2 ± 13.8) years of age and treated with budesonide, 5-ASA, azathioprine and systemic steroids. The different pharmacotherapies had no apparent influence on the results of our assays as analyzed by clustering disease, treatment and gene variations. One-way ANOVA and post-hoc Bonferroni test were applied for analysis. This study was approved by the Ethics Committees of the University of Regensburg and the University of Zurich and performed in accordance with the Declaration of Helsinki.

Cell Lines and Primary Cells
The human embryonal kidney (HEK)293 cell line and the human acute monocytic leukemia cell line MONO-MAC-6 (MM6) were cultured under standard tissue culture conditions as described previously [34]. Surgical specimens from inflamed and normal mucosa were obtained by surgery. The study was approved by the University of Regensburg Ethics Committee. Specimens were obtained from the colons of patients after their agreement. Primary cells were isolated from surgical specimens as described [35, 36]. Briefly, intestinal epithelial cells were isolat-

ed from surgical specimens. Mucosal strips were incubated in 1 mmol/l EDTA (Sigma) for 10 min at 37°C and transferred to tubes. Tubes were shaken vigorously 5–10 times. Mucosal strips were removed by passing the slurry over a coarse mesh (400 μm; Carl Roth GmbH, Karlsruhe, Germany). The suspension containing the detached intestinal epithelial cells was passed over the mesh filter (80-μm pore size; Sefar, Kansas City, Mo., USA), and intact CEC crypts were eluted by inverting the filter in serum-free culture medium (keratinocyte serum-free medium; Gibco-BRL, Eggenstein, Germany).

Specimens for isolation of human lamina propria mononuclear cells (LPMNCs) were incubated for 30 min in 2 ml phosphate-buffered saline (PBS) with 1 mg/ml collagenase type I (= 336 U/ml), 0.3 mg/ml deoxyribonuclease (DNase I, Boehringer, Mannheim, Germany) and 0.2 mg/ml hyaluronidase without fetal calf serum (FCS) at 37°C. Cells were dispersed by passing through a 27-gauge needle by a 1- to 2-ml syringe, washed in 1.5 ml PBS with 500 μl FCS and finally submitted to Ficoll density gradient centrifugation for 20 min at 2,000 rpm ($\approx$ 690 g, without brake) in a Heraeus centrifuge for the isolation of mononuclear cells. The interphase was carefully removed and washed with PBS. Intestinal macrophages were labeled with immunomagnetic microbeads armed with CD33 antibody and purified twice with the help of type AS separation columns (Miltenyi Biotec) as described previously [37].

Peripheral blood lymphocytes and blood monocytes (CD33$^+$) were isolated from healthy volunteers as described previously [36]. The purity of isolated primary cells was always >95%.

RNA Extraction and Quantitative Real-Time PCR
Total RNA was isolated using the RNeasy Mini Kit (#74106, Qiagen) following the manufacturer's recommendations. cDNA was synthesized with a high-capacity cDNA reverse-transcription kit according to the manufacturer's instructions (#4368814, Applied Biosystems). To determine expression, quantitative real-time PCR (qPCR) was performed under the following cycling conditions: 20 s at 95°C, then 45 cycles of 95°C for 3 s and 60°C for 30 s with the TaqMan Fast Universal Mastermix. Primers for real time PCR: MIP-3α for 5′ TGT CAG TGC TGC TAC TCC ACC T 3′, MIP-3α rev 5′ CTG TGT ATC CAA GAC AGC AGT CAA 3′, MIP-3α probe, 6-FAM-5′ TGC GGC GAA TCA GAA GCA GCA A 3′-TAMRA. Human IL-8 (#Hs00174103_m1, PE Applied Biosystems) and GAPDH (#4326317E, PE Applied Biosystems). Each sample was analyzed in triplicate. The comparative $\Delta\Delta C_t$ method was applied to determine the quantity of the target sequences relative to the endogenous control GAPDH and a reference sample.

ELISA
Culture supernatants from MM6 and HEK293 cells were collected after MDP (#A9519, Sigma-Aldrich, Steinheim, Germany) or lipopolysaccharide (LPS) (#62325, Fluka, Buchs, Switzerland) stimulation. The supernatants were centrifuged and used for determination of IL-8 and MIP-3α by commercially available ELISA kits (human IL-8 colorimetric ELISA kit, Pierce, Rockford, Ill., USA and human CCL20/MIP-3α quantikine ELISA kit, R&D Systems, Minneappolis, Minn., USA, respectively).

Vectors, Transfection and Stimulation
For transfection 7.5 × 10^5 HEK293 were seeded in each well of a 6-well plate (Corning Inc., Costar$^®$) in 1.5-ml media. Cells were cultured under standard tissue culture conditions as described above until cells were 60–80% confluent. pcDNA3.1 plasmids with inserts were constructed as described elsewhere [38]. For transient transfection, we used 2-μg expression vectors for NOD2^{WT} gene (pcDNA3.1_NOD2/CARD15) and for NOD2 SNP13 variant (pcDNA3.1_SNP13). The control vector (pcDNA3.1) was from Invitrogen, Carlsbad, USA. Expression vectors were diluted in 97 μl serum-free media in sterile 1.5-ml plastic tubes. 3 μl Fugene 6™ (Roche) was added, mixed and incubated for 10 min at room temperature. The Fugene™-DNA mixture was added to the wells in a drop-wise manner. For transfection control cells were transfected with 2 μg pEGFP vector (BD Biosciences) in a separate well. Transfected cells were incubated for 24 h. For stimulation with MDP (#A9519, Sigma) substance was diluted in 97 μl serum-free media in sterile 1.5-ml plastic tubes. 3 μl Fugene 6™ (Roche) were added, mixed and incubated for 10 min at room temperature. The Fugene™-MDP mixture was added to the wells in a drop-wise manner. For stimulation with LPS (#62325, Fluka) substance was diluted in media containing serum in sterile 1.5-ml plastic tubes. Experiments with transfected HEK293 were terminated after 72 h.

Antibodies
For the identification of human IMACs in immunohistochemistry, mouse anti-human macrophage CD68 (M0814, clone KP1, IgG$_1$κ, monoclonal, DAKO, Hamburg, Germany, final concentration 0.5 μg/ml) was applied. Mouse anti-human CD45R0 (M 0742, clone UCHL1, IgG2a, monoclonal, DAKO, final concentration 0.2 μg/ml) was used to identify human memory cells. Goat anti-human IL-17 (AF-317-NA, IgG, R&D Systems, dilution 1:100) was applied for the identification of human IL-17-positive cells.

Monoclonal mouse anti-human NOD2 (#114445, IgG, Cayman Chemical, Ann Arbor, Mich., USA, dilution 1:1000) and monoclonal mouse anti-human actin (#25060051, IgG1κ, Chemicon International, Temecula, Calif., USA, dilution 1:1,000) were used for Western blots.

Peroxidase-conjugated goat anti-mouse IgG antibody (A-4416, Sigma, final concentration 0.2 μg/ml) or rabbit anti-goat (P0449, DAKO, dilution 1:300) was used as secondary antibody in immunohistochemistry and goat anti-mouse IgG antibody (#sc-2005, Santa Cruz, Heidelberg, dilution 1:5,000) as secondary antibody in Western blotting.

Immunohistochemistry
Surgical specimens in paraffin blocks were cut (5 μm) and mounted on superfrost slides (Menzel-Gläser, Braunschweig, Germany). Sections were deparaffinized in xylene and gradually hydrated. The slides were exposed to 0.3% hydrogen peroxide in PBS for 5 min to inactivate endogenous peroxidase. Sections were treated using the Bond-maX automated staining system (Leica Microsystems). For brown staining, the primary antibody was detected using the Refine DAB method (Vision BioSystems) with an H$_2$ Buffer (Vision BioSystems) heat-induced epitope retrieval (98°C). For red staining, the primary antibody was detected using alkaline phosphatase polymer and new Fuchsine as substrate. Slides were counterstained with hematoxylin, dehydrated and mounted.

Fig. 1. MIP-3α secretion of MM6 incubated with MDP. MM6 were stimulated with increasing concentrations of MDP or vehicle alone. MIP-3α secretion was quantified in the supernatant of these cells by ELISA. Dose-dependent secretion of MIP-3α during 8 h stimulation confirmed our hypothesis that MDP stimulates MIP-3α secretion in myeloid cells. Data were calculated from three independent experiments and are given as mean (SD).

Statistical Analyses

Statistical analyses were performed using PASW statistics 18.0 (SPSS Inc., USA). One-way ANOVA and post-hoc Bonferroni test were applied for analysis of human samples. One-way ANOVA and Kruskal-Wallis one-way ANOVA on ranks were used for primary human cell experiments and human cell lines. Bars represent mean values with Whiskers displaying standard deviation. Differences were considered significant at $p < 0.05$ (cytokine and chemokine levels, quantification of immunohistochemistry). Luminescence of Western blots was quantified densitometrically with OptiQuant (Packard Instrument, USA). For quantitative analysis of cell recruitment in the intestinal mucosa and expression of CD68-, CD45R0- and IL-17-positive cells were counted and calculated from four high-power fields (hpf) at a magnification of ×200.

Results

MDP-Induced MIP-3α Expression in the Myeloid Cell Line MM6

We hypothesized that NOD2 stimulation via MDP is followed by increased MIP-3α secretion in IMACs. To investigate the influence of NOD2-mediated NF-κB activation on MIP-3α expression, we examined its induction in the human myeloid cell line MM6. As positive control IL-8 secretion upon LPS stimulation was confirmed for MM6 cells (online suppl. fig. 1). We stimulated MM6 with

0, 0.001, 0.01, 0.1, 1, 10 and 100 μg/ml MDP. MIP-3α secretion was induced after 8 h stimulation in a dose-dependent manner (fig. 1). This confirmed our hypothesis that MDP stimulates MIP-3α secretion in myeloid cells. To cross-check our hypothesis we examined MIP-3α induction upon MDP stimulation in the NOD2 negative cell line HEK293T. HEK293T cells were stimulated in a single experiment for 24 h with 1 μg/ml MDP. No induction of MIP-3α and IL-8 secretion was obtained compared to nonstimulated cells (not shown).

NOD2 Variants Impair MDP-Mediated MIP-3α Induction

To investigate the influence of NOD2 on the expression of MIP-3α, we transfected HEK293T with SNP13 variants. One variant expressed the NOD2[WT] gene (pcDNA3.1_NOD2/CARD15) and the second expressed the NOD2 SNP13 variant (pcDNA3.1_SNP13). The 'empty' vector backbone served as control (pcDNA3.1). NOD2 expression in transiently transfected HEK293T was confirmed by Western blot (online suppl. fig. 2). Cells were stimulated with MDP. To confirm NF-κB activation IL-8 secretion was measured (not shown). MIP-3α expression was significantly ($p < 0.05$) induced by 1,000 ng/ml MDP stimulation (fig. 2). We also determined increased expression of MIP-3α mRNA upon expression of NOD2 SNP13 variant compared to vector control.

NOD2-dependent secretion of MIP-3α into the supernatant was also confirmed by ELISA. Cells expressing the control plasmid did not show any changes in basal MIP-3α secretion. Expression of both NOD2[WT] gene and NOD2 SNP13 variant resulted in a significantly ($p < 0.05$) elevated MIP-3α secretion (6.2- and 3.2-fold compared to control, respectively; fig. 3). MIP-3α mRNA expression was significantly ($p < 0.05$) induced by 100 ng/ml MDP stimulation for NOD2[WT] gene (19.9-fold compared to unstimulated cells also transfected with NOD2[WT] gene; fig. 3). Higher MDP concentrations led to an increase in the secretion of MIP-3α in NOD2 SNP13 variant transfected HEK293T, achieving the values for NOD2[WT] gene following MDP stimulation with 1,000 and 2,000 ng/ml MDP. These results confirmed our hypothesis that MDP stimulates MIP-3α secretion in a NOD2 variant-dependent manner.

MIP-3α mRNA Expression in Human Intestinal Mucosa

Previously, in an ex vivo model, we demonstrated that induction of MIP-3α during differentiation of human IMACs is followed by increased migration of CD45R0[+] T

Fig. 2. Levels of MIP-3α mRNA in MDP-stimulated HEK293T. HEK293T were transiently transfected with pcDNA3.1 (control, white column), pcDNA3.1_NOD2/CARD15 (NOD2/CARD15 WT gene, light grey column) or pcDNA3.1_SNP13 (NOD2/CARD15 mutation SNP13, dark grey column) and stimulated with increasing concentrations of MDP. Real-time PCR shows that overexpression of both NOD2 and NOD2 SNP13 gene variants resulted in increased MIP-3α mRNA. The expression of the WT gene led to a significant (* $p < 0.05$) induction of MIP-3α mRNA by stimulation with 1,000 ng/ml MDP compared to unstimulated cells. Data were calculated from four independent experiments and are given as mean (SD). One-way ANOVA and Kruskal-Wallis one-way ANOVA on ranks were used.

Fig. 3. ELISA: Secretion of MIP-3α in MDP stimulated HEK293T. HEK293T were transiently transfected with pcDNA3.1 (control), pcDNA3.1_NOD2/CARD15 (NOD2/CARD15 WT gene) or pcDNA3.1_SNP13 (NOD2/CARD15 mutation SNP13) and stimulated with increasing concentrations of MDP. Overexpression of both NOD2 gene variants resulted in an increased MIP-3α production. The expression of the WT gene led to a significant (* $p < 0.05$) induction of MIP-3α secretion by stimulation with 100 ng/ml MDP compared to the empty vector. Data were calculated from three independent experiments and are given as mean (SD). One-way ANOVA and Kruskal-Wallis one-way ANOVA on ranks were used.

cells. We hypothesized that MIP-3α expression is also induced in IMACs in vivo during their differentiation in the lamina propria followed by the recruitment of CCR6[+] cells. To confirm this hypothesis, MIP-3α mRNA expression was determined by real-time PCR in primary intestinal epithelial cells, LPMNCs and IMACs isolated from human intestinal mucosa from surgical specimens. To keep procedures similar, monocytes and intestinal macrophages were isolated via CD33, a unique surface marker present on both. Real-time PCR for MIP-3α mRNA synthesis showed high expression levels for both intestinal epithelial cells (17.6 ± 1.1 relative to blood lymphocytes set as one; fig. 4) and IMACs (12.4 ± 0.9). Similar MIP-3α mRNA expression levels were obtained from LPMNCs, including IMACs (11.9 ± 1.1). LPMNCs depleted of IMACs showed low MIP-3α mRNA expression levels (6.1 ± 1.1). Levels of MIP-3α mRNA synthesis found in peripheral blood lymphocytes were set as one and used as the control (fig. 4). Similarly, the level of MIP-3α mRNA expression was obtained from human blood monocytes isolated from peripheral blood lymphocytes (0 ± 0.5).

Recruitment of CD45R0[+] and Th17 Cells Is Not Affected by Heterozygous NOD2 Gene Variants

Breakdown of the epithelial barrier and successive influx of bacterial wall components seem to play an essential role in the pathogenesis of CD. In vitro MDP is able to activate the NF-κB pathway via NOD2 followed by the release of MIP-3α, resulting in memory T lymphocyte recruitment. The in vitro experiments described above showed a functional deficit in MIP-3α expression in cells transfected with NOD2 variant SNP13. Since MIP-3α may be involved in the aggregation of CCR6[+] lymphocytes during an immune response, we consequently investigated the recruitment of CD45R0[+] cells and Th17 cells with respect to NOD2 genotypes. Immunohistochemistry showed that cell-cell contacts between IMACs and CD45R0[+] memory T cells showed no difference between patients with NOD2[WT] gene (34.7 ± 17.8 cells/hpf) and patients with heterozygous mutations in NOD2 (31.8 ± 16.4 for SNP8, 53.0 ± 26.4 for SNP12, and 41.5 ± 20.2 cells/hpf for SNP13; fig. 5). Recruitment of Th17 cells was unchanged in patients with NOD2[WT] (12.5 ± 12.8 cells/

Fig. 4. MIP-3α mRNA expression determined by real-time PCR. Cells were isolated as described in 'Materials and Methods'. Peripheral blood lymphocytes were set as zero. Differentiation of monocytes from the peripheral blood into IMACs led to a significant (* $p < 0.05$) induction of MIP-3α mRNA expression. Similar expression levels were found in intestinal epithelial cells. Expression data are given relative to a representative blood monocyte sample set to zero. One-way ANOVA, Kruskal-Wallis one-way ANOVA on ranks.

hpf) and patients with heterozygous mutations in NOD2 (12.4 ± 7.7 for SNP8, 14.2 ± 4.3 for SNP12, and 20.0 ± 12.1 cells/hpf for SNP13; fig. 6).

Discussion

Disturbance of the mucosal barrier and mucosal transport processes is thought to be a major factor in the pathogenesis of intestinal inflammation and IBD. Increased permeability of the epithelial barrier in ulcerative colitis and CD has been reported [39–42]. Local protection mechanisms of the healthy mucosa prevent the invasion of bacteria or specific pathogens from the intestinal lumen into the body. Protective factors such as mucus production [43] and synthesis of antimicrobial peptides are impaired in CD. The intestinal barrier becomes 'leaky', resulting in the invasion of luminal antigen. A number of knockout models of IBD confirm that bacteria are essential for the development of intestinal inflammation [44–46]. NOD2 is an intracellular sensor of bacterial MDP that has been shown to be the most important susceptibility factor for the onset and pathogenesis of CD.

NOD2 is able to activate the NF-κB pathway followed by the release of MIP-3α, which attracts memory T lymphocytes [17–23].

In this study, we therefore asked (1) whether the expression of MIP-3α is associated with the NOD2 genotype and (2) what consequence stimulation with bacterial antigen after mucosal translocation has on recruitment of CCR6-positive immune cells.

We found that NOD2 stimulation via MDP was followed by a dose-dependent increase in MIP-3α secretion in the myeloid cell line MM6. No induction of MIP-3α secretion was obtained in NOD2-negative HEK293 upon MDP stimulation but in vitro, MIP-3α mRNA was significantly ($p < 0.05$) induced in HEK293 transfected with NOD2_pcDNA via MDP ligation. Increased MIP-3α protein secretion was confirmed by ELISA. In vivo, MIP-3α protein expression in human intestinal epithelial cells and IMACs was determined in a nonquantitative manner by immunohistochemistry and flow cytometry [31]. In this work, we could confirm MIP-3α mRNA expression ex vivo in freshly isolated intestinal epithelial cells and IMACs. MIP-3α mRNA expression was significantly ($p < 0.05$) higher in primary human IMACs in comparison to monocytes. Previous in vitro experiments showed a functional deficit in Mip-3α expression in HEK293 cells transfected with NOD2 variant SNP13. We therefore investigated Th17 and memory cell recruitment with respect to NOD2 variants. In vivo cell-cell contacts between IMACs and CD45R0[+] and recruitment of Th17 cells was unchanged in patients with heterozygous NOD2 variants as compared to NOD2[WT] individuals.

Altered immunological responses in the gut during inflammation and under normal conditions are reflected by different PRR subsets of IMACs and DCs. It seems unlikely that in CD only a single reactive endotoxin component accumulates in the mucosa. Multiple pathogen-associated molecular patterns or microbe-associated molecular patterns are detected by a number of PRRs shown to be expressed extracellularly. Intracellularly, a repertoire of PRRs accounts for NF-κB-driven immunological competence of IMACs and DCs during inflammation. Recognition of endotoxin induces a Th1 or Th17 proinflammatory immune response directed normally at pathogens [47–49]. Due to their expansion or homing Th17 cells are highly enriched in the intestine. Th17 cells express various trafficking receptors, but the MIP-3α receptor CCR6 is uniformly expressed by all subsets of Th17 cells. In mice, CCR6[−/−] Th17 cells are less efficient in migration to small intestinal lamina propria [50]. Short-term migration of CCR6[−/−] Th17 cells to the large

Fig. 5. Immunohistochemistry for CD68 (brown) and CD45R0 (red). **a** NOD2^{WT}. **b** SNP8. **c** SNP12. **d** SNP13. ×200. **e** Recruitment of CD45R0+ memory T cells (white columns) and cell-cell-contacts between memory T cells and IMACs (grey columns). Cells were counted in four high-power fields. One-way ANOVA and post-hoc Bonferroni test were applied for analysis.

Fig. 6. Immunohistochemistry for IL-17 (brown). **a** NOD2^{WT}. **b** SNP8. **c** SNP12. **d** SNP13. ×200. **e** Recruitment of Th17 cells. Cells were counted in four high-power fields. One-way ANOVA and post-hoc Bonferroni test were applied for analysis.

intestine is not decreased. However, significantly fewer Th17 cells and an aberrant increase of Th1 cells are found in the intestine of Rag1$^{-/-}$ SCID mice injected with CCR6$^{-/-}$ Th17 cells compared to WT Th17 cells. Consistently, CCR6$^{-/-}$ Th17 cells induce more severe intestinal inflammation in Rag1$^{-/-}$ SCID mice [50]. CCR6 is not the only trafficking receptor that is important for migration and localization in the gut.

On the other hand, under normal conditions, 'tolerant' IMACs and DCs lack antigens connected with the recep-

tion of inflammatory signals [36, 37]. MyD88, TRIF adapter proteins and TRAF6 are undetectable or reduced [51] which is consistent with a low activation of NF-κB [2]. This is followed by an impaired NF-κB-mediated function [52, 53]. Further, IMACs and DCs lack antigens necessary for transmission of inflammatory signals [1, 36]. Ineffective TLR activation in 'tolerant' IMACs and DCs place non-MyD88 mediated signaling in the center of interest. TLRs and NOD2 activate the transcription factor NF-κB in a redundant manner, thus especially under normal conditions and during times of remission with a lack of signaling via TLRs, functional variants of NOD2 may have greater impact on the maintenance of defense. Despite the fact that NOD2 is expressed intracellularly, extracellularly bacteria can also be recognized by NOD2 through a plasma membrane transporter hPepT1 [54, 55]. We proposed that absence or downregulation of NF-κB-driven MIP-3α may initiate or worsen inflammation. Data from this work demonstrate an increase in MIP-3α secretion upon MDP stimulation. Under normal conditions we supposed that this is NOD2 mediated in 'tolerant' IMACs and DCs because these cells lack other PRRs. But recruitment of Th17 cells or CD45R0+ memory T lymphocytes is not altered in heterozygous NOD2 variants. A recent study has shown the possible interplay between NOD-like receptors and other PRRs in epithelia: in the absence of one receptor, epithelial cells show upregulated expression of other receptors to compensate for the absent receptor [56]. Interplay of NOD-like receptors, protease-activated receptors (PAR2) and TLRs in the induction of MIP-3α in response to various bacteria has been reported [56]. NOD2 can compensate for the lack of cell-surface receptors PAR1 and PAR2 in epithelial response to bacteria. Synergism of signaling via NOD2 and other PRRs in monocytic THP-1 cells has also been reported recently [57].

In summary, these data clearly demonstrate a dose-dependent increase in MIP-3α secretion upon MDP stimulation. Similarly, we show that HEK293T cells are sensitized to bacterial stimuli solely by overexpressing NOD2, as indicated by an increased secretion of MIP-3α. We have tested the ability that bacterial sensing and subsequent recruitment of Th17 cells or CD45R0+ memory T lymphocytes is altered in patients carrying loss-of-function variants in the NOD2 gene. The total number of cell subsets was not significantly altered, indicating that secondary Th17 cell recruitment is not affected by the defect in innate immunity. Cell-cell contacts between CD45R0+ memory T cells and IMACs were not modified in patients carrying heterozygous NOD2 mutations and patients carrying the WT gene.

NOD2 polymorphisms have been identified as risk factors of graft-versus-host disease (GVHD) following allogeneic stem cell transplantation. Recent work shows that intestinal GVHD is associated with a stage-dependent decrease in CD4 T cell infiltrates in the lamina propria [58]. The presence of NOD2 variants in the recipient is associated with a significant loss of CD4 T cells. Therefore, in future work it will be necessary to consider recruitment of other subpopulations of CCR6+ cells. Next to CCR6+ DCs and B lymphocytes recruitment of tissue CCR6+CD4+ T cells might be of interest.

Disclosure Statement

G. Rogler discloses grant support from Abbott, Ardeypharm, Essex, FALK, Flamentera, Novartis, Tillots, UCB and Zeller.

References

1 Rugtveit J, Bakka A, Brandtzaeg P: Differential distribution of B7.1 (CD80) and B7.2 (CD86) costimulatory molecules on mucosal macrophage subsets in human inflammatory bowel disease (IBD). Clin Exp Immunol 1997;110:104–113.

2 Rogler G, Brand K, Vogl D, Page S, Hofmeister R, Andus T, Knuechel R, Baeuerle PA, Scholmerich J, Gross V: Nuclear factor kappaB is activated in macrophages and epithelial cells of inflamed intestinal mucosa. Gastroenterology 1998;115:357–369.

3 Bonen DK, Ogura Y, Nicolae DL, Inohara N, Saab L, Tanabe T, Chen FF, Foster SJ, Duerr RH, Brant SR, Cho JH, Nunez G: Crohn's disease-associated NOD2 variants share a signaling defect in response to lipopolysaccharide and peptidoglycan. Gastroenterology 2003;124:140–146.

4 Inohara N, Ogura Y, Fontalba A, Gutierrez O, Pons F, Crespo J, Fukase K, Inamura S, Kusumoto S, Hashimoto M, Foster SJ, Moran AP, Fernandez-Luna JL, Nunez G: Host recognition of bacterial muramyl dipeptide mediated through NOD2. Implications for Crohn's disease. J Biol Chem 2003;278:5509–5512.

5 Rosenstiel P, Fantini M, Brautigam K, Kuhbacher T, Waetzig GH, Seegert D, Schreiber S: TNF-alpha and IFN-gamma regulate the expression of the NOD2 (card15) gene in human intestinal epithelial cells. Gastroenterology 2003;124:1001–1009.

6 Hisamatsu T, Suzuki M, Reinecker HC, Nadeau WJ, McCormick BA, Podolsky DK: Card15/NOD2 functions as an antibacterial factor in human intestinal epithelial cells. Gastroenterology 2003;124:993–1000.

7 Harant H, Eldershaw SA, Lindley IJ: Human macrophage inflammatory protein-3alpha/ CCL20/LARC/exodus/SCYA20 is transcriptionally upregulated by tumor necrosis factor-alpha via a non-standard NF-kappaB site. FEBS Lett 2001;509:439–445.

8 Jaramillo M, Olivier M: Hydrogen peroxide induces murine macrophage chemokine gene transcription via extracellular signal-regulated kinase- and cyclic adenosine 5′-monophosphate (cAMP)-dependent pathways: involvement of NF- kappa B, activator protein 1, and cAMP response element binding protein. J Immunol 2002;169:7026–7038.

9 Sugita S, Kohno T, Yamamoto K, Imaizumi Y, Nakajima H, Ishimaru T, Matsuyama T: Induction of macrophage-inflammatory protein-3alpha gene expression by TNF-dependent NF-kappaB activation. J Immunol 2002;168:5621–5628.

10 Hugot JP, Chamaillard M, Zouali H, Lesage S, Cezard JP, Belaiche J, Almer S, Tysk C, O'Morain CA, Gassull M, Binder V, Finkel Y, Cortot A, Modigliani R, Laurent-Puig P, Gower-Rousseau C, Macry J, Colombel JF, Sahbatou M, Thomas G: Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease. Nature 2001; 411:599–603.

11 Ogura Y, Bonen DK, Inohara N, Nicolae DL, Chen FF, Ramos R, Britton H, Moran T, Karaliuskas R, Duerr RH, Achkar JP, Brant SR, Bayless TM, Kirschner BS, Hanauer SB, Nunez G, Cho JH: A frameshift mutation in NOD2 associated with susceptibility to Crohn's disease. Nature 2001;411:603–606.

12 Hugot JP: Card15/NOD2 mutations in Crohn's disease. Ann N Y Acad Sci 2006; 1072:9–18.

13 Li J, Moran T, Swanson E, Julian C, Harris J, Bonen DK, Hedl M, Nicolae DL, Abraham C, Cho JH: Regulation of IL-8 and IL-1beta expression in Crohn's disease associated NOD2/CARD15 mutations. Hum Mol Genet 2004;13:1715–1725.

14 Kosovac K, Brenmoehl J, Holler E, Falk W, Schoelmerich J, Hausmann M, Rogler G: Association of the NOD2 genotype with bacterial translocation via altered cell-cell contacts in Crohn's disease patients. Inflamm Bowel Dis 2010;16:1311–1321.

15 Hieshima K, Imai T, Opdenakker G, Van Damme J, Kusuda J, Tei H, Sakaki Y, Takatsuki K, Miura R, Yoshie O, Nomiyama H: Molecular cloning of a novel human CC chemokine liver and activation-regulated chemokine (LARC) expressed in liver. Chemotactic activity for lymphocytes and gene localization on chromosome 2. J Biol Chem 1997;272:5846–5853.

16 Hromas R, Gray PW, Chantry D, Godiska R, Krathwohl M, Fife K, Bell GI, Takeda J, Aronica S, Gordon M, Cooper S, Broxmeyer HE, Klemsz MJ: Cloning and characterization of exodus, a novel beta-chemokine. Blood 1997;89:3315–3322.

17 Caux C, Vanbervliet B, Massacrier C, Ait-Yahia S, Vaure C, Chemin K, Dieu-Nosjean MC, Vicari A: Regulation of dendritic cell recruitment by chemokines. Transplantation 2002;73:S7–S11.

18 Charbonnier AS, Kohrgruber N, Kriehuber E, Stingl G, Rot A, Maurer D: Macrophage inflammatory protein 3alpha is involved in the constitutive trafficking of epidermal Langerhans cells. J Exp Med 1999;190:1755–1768.

19 Dieu MC, Vanbervliet B, Vicari A, Bridon JM, Oldham E, Ait-Yahia S, Briere F, Zlotnik A, Lebecque S, Caux C: Selective recruitment of immature and mature dendritic cells by distinct chemokines expressed in different anatomic sites. J Exp Med 1998; 188:373–386.

20 Dieu-Nosjean MC, Massacrier C, Homey B, Vanbervliet B, Pin JJ, Vicari A, Lebecque S, Dezutter-Dambuyant C, Schmitt D, Zlotnik A, Caux C: Macrophage inflammatory protein 3alpha is expressed at inflamed epithelial surfaces and is the most potent chemokine known in attracting Langerhans cell precursors. J Exp Med 2000;192:705–718.

21 Dieu-Nosjean MC, Vicari A, Lebecque S, Caux C: Regulation of dendritic cell trafficking: a process that involves the participation of selective chemokines. J Leukoc Biol 1999; 66:252–262.

22 Greaves DR, Wang W, Dairaghi DJ, Dieu MC, Saint-Vis B, Franz-Bacon K, Rossi D, Caux C, McClanahan T, Gordon S, Zlotnik A, Schall TJ: CCR6, a CC chemokine receptor that interacts with macrophage inflammatory protein 3alpha and is highly expressed in human dendritic cells. J Exp Med 1997;186:837–844.

23 Iwasaki A, Kelsall BL: Freshly isolated Peyer's patch, but not spleen, dendritic cells produce interleukin 10 and induce the differentiation of T helper type 2 cells. J Exp Med 1999;190:229–239.

24 Baba M, Imai T, Nishimura M, Kakizaki M, Takagi S, Hieshima K, Nomiyama H, Yoshie O: Identification of CCR6, the specific receptor for a novel lymphocyte- directed CC chemokine LARC. J Biol Chem 1997;272:14893–14898.

25 Bowman EP, Campbell JJ, Soler D, Dong Z, Manlongat N, Picarella D, Hardy RR, Butcher EC: Developmental switches in chemokine response profiles during B cell differentiation and maturation. J Exp Med 2000;191:1303–1318.

26 Fitzhugh DJ, Naik S, Caughman SW, Hwang ST: Cutting edge: C-C chemokine receptor 6 is essential for arrest of a subset of memory T cells on activated dermal microvascular endothelial cells under physiologic flow conditions in vitro. J Immunol 2000;165:6677–6681.

27 Liao F, Rabin RL, Smith CS, Sharma G, Nutman TB, Farber JM: CC-chemokine receptor 6 is expressed on diverse memory subsets of T cells and determines responsiveness to macrophage inflammatory protein 3 alpha. J Immunol 1999;162:186–194.

28 Power CA, Church DJ, Meyer A, Alouani S, Proudfoot AE, Clark-Lewis I, Sozzani S, Mantovani A, Wells TN: Cloning and characterization of a specific receptor for the novel CC chemokine mip-3alpha from lung dendritic cells. J Exp Med 1997;186:825–835.

29 Annunziato F, Cosmi L, Santarlasci V, Maggi L, Liotta F, Mazzinghi B, Parente E, Fili L, Ferri S, Frosali F, Giudici F, Romagnani P, Parronchi P, Tonelli F, Maggi E, Romagnani S: Phenotypic and functional features of human Th17 cells. J Exp Med 2007;204:1849–1861.

30 Schutyser E, Struyf S, Menten P, Lenaerts JP, Conings R, Put W, Wuyts A, Proost P, Van Damme J: Regulated production and molecular diversity of human liver and activation-regulated chemokine/macrophage inflammatory protein-3 alpha from normal and transformed cells. J Immunol 2000;165: 4470–4477.

31 Hausmann M, Bataille F, Spoettl T, Schreiter K, Falk W, Schoelmerich J, Herfarth H, Rogler G: Physiological role of macrophage inflammatory protein-3 alpha induction during maturation of intestinal macrophages. J Immunol 2005;175:1389–1398.

32 Izadpanah A, Dwinell MB, Eckmann L, Varki NM, Kagnoff MF: Regulated mip-3alpha/ CCl20 production by human intestinal epithelium: Mechanism for modulating mucosal immunity. Am J Physiol Gastrointest Liver Physiol 2001;280:G710–719.

33 Kwon JH, Keates S, Bassani L, Mayer LF, Keates AC: Colonic epithelial cells are a major site of macrophage inflammatory protein 3alpha (mip-3alpha) production in normal colon and inflammatory bowel disease. Gut 2002;51:818–826.

34 Spoettl T, Paetzel C, Herfarth H, Bencherif M, Schoelmerich J, Greinwald R, Gatto GJ, Rogler G: (E)-metanicotine hemigalactarate (TC-2403–12) inhibits IL-8 production in cells of the inflamed mucosa. Int J Colorectal Dis 2007;22:303–312.

35 Kiessling S, Muller-Newen G, Leeb SN, Hausmann M, Rath HC, Strater J, Spottl T, Schlottmann K, Grossmann J, Montero-Julian FA, Scholmerich J, Andus T, Buschauer A, Heinrich PC, Rogler G: Functional expression of the interleukin-11 receptor alpha-chain and evidence of antiapoptotic effects in human colonic epithelial cells. J Biol Chem 2004;279:10304–10315.

36 Rogler G, Hausmann M, Vogl D, Aschenbrenner E, Andus T, Falk W, Andreesen R, Scholmerich J, Gross V: Isolation and phenotypic characterization of colonic macrophages. Clin Exp Immunol 1998;112:205–215.

37 Hausmann M, Kiessling S, Mestermann S, Webb G, Spottl T, Andus T, Scholmerich J, Herfarth H, Ray K, Falk W, Rogler G: Toll-like receptors 2 and 4 are up-regulated during intestinal inflammation. Gastroenterology 2002;122:1987–2000.

38 Weichart D, Gobom J, Klopfleisch S, Hasler R, Gustavsson N, Billmann S, Lehrach H, Seegert D, Schreiber S, Rosenstiel P: Analysis of NOD2-mediated proteome response to muramyl dipeptide in HEK293 cells. J Biol Chem 2006;281:2380–2389.

39 Rask-Madsen J: Sieving characteristics of inflamed rectal mucosa. Gut 1973;14:988–989.

40 Hagiwara C, Tanaka M, Kudo H: Increase in colorectal epithelial apoptotic cells in patients with ulcerative colitis ultimately requiring surgery. J Gastroenterol Hepatol 2002;17:758–764.

41 Hollander D, Vadheim CM, Brettholz E, Petersen GM, Delahunty T, Rotter JI: Increased intestinal permeability in patients with Crohn's disease and their relatives. A possible etiologic factor. Ann Intern Med 1986;105:883–885.

42 Zeissig S, Bojarski C, Buergel N, Mankertz J, Zeitz M, Fromm M, Schulzke JD: Downregulation of epithelial apoptosis and barrier repair in active Crohn's disease by tumour necrosis factor alpha antibody treatment. Gut 2004;53:1295–1302.

43 Strugala V, Dettmar PW, Pearson JP: Thickness and continuity of the adherent colonic mucus barrier in active and quiescent ulcerative colitis and Crohn's disease. Int J Clin Pract 2008;62:762–769.

44 Rath HC, Herfarth HH, Ikeda JS, Grenther WB, Hamm TE Jr, Balish E, Taurog JD, Hammer RE, Wilson KH, Sartor RB: Normal luminal bacteria, especially Bacteroides species, mediate chronic colitis, gastritis, and arthritis in HLA-B27/human beta2 microglobulin transgenic rats. J Clin Invest 1996;98:945–953.

45 Sellon RK, Tonkonogy S, Schultz M, Dieleman LA, Grenther W, Balish E, Rennick DM, Sartor RB: Resident enteric bacteria are necessary for development of spontaneous colitis and immune system activation in interleukin-10-deficient mice. Infect Immun 1998;66:5224–5231.

46 Dianda L, Hanby AM, Wright NA, Sebesteny A, Hayday AC, Owen MJ: T cell receptor-alpha beta-deficient mice fail to develop colitis in the absence of a microbial environment. Am J Pathol 1997;150:91–97.

47 Uhlig HH, Powrie F: Dendritic cells and the intestinal bacterial flora: a role for localized mucosal immune responses. J Clin Invest 2003;112:648–651.

48 Strober W, Fuss IJ, Blumberg RS: The immunology of mucosal models of inflammation. Annu Rev Immunol 2002;20:495–549.

49 Steinman L: A brief history of T(h)17, the first major revision in the T(h)1/T(h)2 hypothesis of T cell-mediated tissue damage. Nat Med 2007;13:139–145.

50 Wang C, Kang SG, Lee J, Sun Z, Kim CH: The roles of CCR6 in migration of Th17 cells and regulation of effector T-cell balance in the gut. Mucosal Immunol 2009;2:173–183.

51 Smythies LE, Shen R, Bimczok D, Novak L, Clements RH, Eckhoff DE, Bouchard P, George MD, Hu WK, Dandekar S, Smith PD: Inflammation anergy in human intestinal macrophages is due to Smad-induced IkappaBalpha expression and NF-kappaB inactivation. J Biol Chem 2010;285:19593–19604.

52 Rugtveit J, Haraldsen G, Hogasen AK, Bakka A, Brandtzaeg P, Scott H: Respiratory burst of intestinal macrophages in inflammatory bowel disease is mainly caused by CD14+L1+ monocyte derived cells. Gut 1995;37:367–373.

53 Hausmann M, Spottl T, Andus T, Rothe G, Falk W, Scholmerich J, Herfarth H, Rogler G: Subtractive screening reveals up-regulation of NADPH oxidase expression in Crohn's disease intestinal macrophages. Clin Exp Immunol 2001;125:48–55.

54 Vavricka SR, Musch MW, Chang JE, Nakagawa Y, Phanvijhitsiri K, Waypa TS, Merlin D, Schneewind O, Chang EB: HpepT1 transports muramyl dipeptide, activating NF-kappaB and stimulating IL-8 secretion in human colonic Caco2/bbe cells. Gastroenterology 2004;127:1401–1409.

55 Ismair MG, Vavricka SR, Kullak-Ublick GA, Fried M, Mengin-Lecreulx D, Girardin SE: HpepT1 selectively transports muramyl dipeptide but not NOD1-activating muramyl peptides. Can J Physiol Pharmacol 2006;84:1313–1319.

56 Chung WO, An JY, Yin L, Hacker BM, Rohani MG, Dommisch H, DiJulio DH: Interplay of protease-activated receptors and NOD pattern recognition receptors in epithelial innate immune responses to bacteria. Immunol Lett 2010;131:113–119.

57 Uehara A, Imamura T, Potempa J, Travis J, Takada H: Gingipains from porphyromonas gingivalis synergistically induce the production of proinflammatory cytokines through protease-activated receptors with toll-like receptor and NOD1/2 ligands in human monocytic cells. Cell Microbiol 2008;10:1181–1189.

58 Landfried K, Bataille F, Rogler G, Brenmoehl J, Kosovac K, Wolff D, Hilgendorf I, Hahn J, Edinger M, Hoffmann P, Obermeier F, Schoelmerich J, Andreesen R, Holler E: Recipient NOD2/CARD15 status affects cellular infiltrates in human intestinal graft-versus-host disease. Clin Exp Immunol 2010;159:87–92.